ArticleCurrent oncology (Toronto, Ont.)2022
The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center.
Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Increasing time-to-treatment for resectable non-small cell lung cancer: Predictors and survival impact.JTCVS open · 2026Article
- Impact of the COVID-19 Pandemic on Lung Cancer Screening and Diagnosis: A Systematic Review.Cancers · 2026Review
- Decomposing life expectancy changes in Spain in the COVID-19 pandemic and post-pandemic periods.BMC public health · 2025Article
- Impact of the COVID-19 Pandemic on Diagnosis and Multidisciplinary Treatment of NSCLC in Ontario, Canada.JTO clinical and research reports · 2025Article
- The Impact of the COVID-19 Pandemic on New Lung Cancer Diagnosis in Mureș County, Romania: A 5-Year Retrospective, Comprehensive Study.Medicina (Kaunas, Lithuania) · 2025Article
- Lung Cancer Under Siege in Spain: Timeliness, Treatment, and Survival Before and After the COVID-19 Pandemic.Cancers · 2025Article
- Delays in phases of care from identification to treatment of suspicious lung nodules.JTCVS open · 2025Article
- Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in Mexico.PharmacoEconomics - open · 2024Article
- Predicting malignant potential of solitary pulmonary nodules in patients with COVID-19 infection: a comprehensive analysis of CT imaging and tumor markers.BMC infectious diseases · 2024Article
- Diagnostic and therapeutic delays in lung cancer during the COVID-19 pandemic: a single center experience at a German Cancer center.BMC pulmonary medicine · 2024Article
- Real-World Evidence of the Impact of the COVID-19 Pandemic on Lung Cancer Survival: Canadian Perspective.Current oncology (Toronto, Ont.) · 2024Article
- Impact of the COVID-19 pandemic on lung cancer diagnosis in northern Poland-addressing the COVID-19 debt.PloS one · 2024Article
- COVID-19 and lung cancer.Pathologica · 2023Review
- Impact of COVID-19 on Timeliness of Receiving Systemic Therapy for Patients Diagnosed with Lung Cancer.Journal of cancer research and practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe have recently reported a 35% drop in new lung cancer diagnoses and a 64% drop in lung cancer surgeries during the first year of the pandemic.
methodsThe target population was divided into three cohorts: pre-COVID-19 (2019), first year of COVID-19 (2020), and second year of COVID-19 (2021).
resultsThe number of new lung cancer diagnoses during the second year of the pandemic increased by 75%, with more than 50% being in the advanced/metastatic stage. There was a significant increase in cases with multiple extrathoracic sites of metastases during the pandemic. During the first year of the pandemic, significantly more patients were treated with radiosurgery compared to the pre-COVID-19 year. During the second year, the number of radiosurgery and surgical cases returned to pre-COVID-19 levels. No significant changes were observed in systemic chemotherapy and targeted therapy. No statistical difference was identified in the mean wait time for diagnosis and treatment during the three years of observation. However, the wait time for surgery was prolonged compared to the pre-COVID-19 cohort.
conclusionsThe significant drop in new diagnoses of lung cancer during the first year of the pandemic was followed by an almost two-fold increase in the second year, with the increased rate of metastatic disease with multiple extra-thoracic site metastases. Limited access to surgery resulted in the more frequent use of radiosurgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.